Amundi Has $9.57 Million Stock Position in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Amundi increased its holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC) by 8.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,908 shares of the company’s stock after acquiring an additional 7,941 shares during the period. Amundi owned about 0.33% of iRhythm Technologies worth $9,570,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of iRhythm Technologies in the fourth quarter worth approximately $45,000. Van ECK Associates Corp grew its holdings in iRhythm Technologies by 41.3% during the fourth quarter. Van ECK Associates Corp now owns 554 shares of the company’s stock worth $50,000 after buying an additional 162 shares in the last quarter. Quarry LP purchased a new stake in iRhythm Technologies in the 3rd quarter valued at $59,000. Nisa Investment Advisors LLC lifted its stake in iRhythm Technologies by 166.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,037 shares of the company’s stock valued at $94,000 after acquiring an additional 648 shares in the last quarter. Finally, KBC Group NV boosted its holdings in iRhythm Technologies by 45.1% during the 4th quarter. KBC Group NV now owns 1,319 shares of the company’s stock worth $119,000 after acquiring an additional 410 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Canaccord Genuity Group increased their target price on shares of iRhythm Technologies from $125.00 to $152.00 and gave the company a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company increased their price objective on shares of iRhythm Technologies from $86.00 to $104.00 and gave the company an “equal weight” rating in a research note on Friday, February 21st. Truist Financial boosted their target price on iRhythm Technologies from $111.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. StockNews.com raised iRhythm Technologies from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Finally, Needham & Company LLC boosted their price objective on iRhythm Technologies from $125.00 to $138.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.73.

iRhythm Technologies Stock Up 3.0 %

Shares of NASDAQ IRTC opened at $100.67 on Friday. The company has a debt-to-equity ratio of 9.00, a current ratio of 6.27 and a quick ratio of 6.12. The stock has a market capitalization of $3.16 billion, a PE ratio of -27.66 and a beta of 1.36. iRhythm Technologies, Inc. has a one year low of $55.92 and a one year high of $128.52. The business’s fifty day moving average price is $106.75 and its 200-day moving average price is $87.46.

iRhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings data on Thursday, February 20th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.30. The business had revenue of $164.33 million for the quarter, compared to the consensus estimate of $158.30 million. iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. On average, equities research analysts anticipate that iRhythm Technologies, Inc. will post -1.98 EPS for the current year.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.